Literature DB >> 19075253

Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma.

Ingrid Alexandre, Bertrand Billemont, Jean Baptiste Meric, Stephane Richard, Olivier Rixe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19075253     DOI： 10.1200/JCO.2008.20.1087

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  Case: Secondary polycythemia due to pazopanib in patients with metastatic renal cell carcinoma.

Authors:  Nedal Bukhari; Eric Winquist
Journal:  Can Urol Assoc J       Date:  2017-11       Impact factor: 1.862

2.  Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.

Authors:  Andrew X Zhu; Dan G Duda; Marek Ancukiewicz; Emmanuelle di Tomaso; Jeffrey W Clark; Rebecca Miksad; Charles S Fuchs; David P Ryan; Rakesh K Jain
Journal:  Clin Cancer Res       Date:  2010-09-15       Impact factor: 12.531

3.  Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.

Authors:  Sumita S Bhatta; Kristen E Wroblewski; Kelly L Agarwal; Laura Sit; Ezra E W Cohen; Tanguy Y Seiwert; Theodore Karrison; George L Bakris; Mark J Ratain; Everett E Vokes; Michael L Maitland
Journal:  Oncologist       Date:  2013-07-30

Review 4.  Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities.

Authors:  Roger B Cohen; Stéphane Oudard
Journal:  Invest New Drugs       Date:  2012-02-12       Impact factor: 3.850

5.  Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.

Authors:  Yutaka Fujiwara; Naomi Kiyota; Naoko Chayahara; Akiyuki Suzuki; Yoshiko Umeyama; Toru Mukohara; Hironobu Minami
Journal:  Invest New Drugs       Date:  2011-02-08       Impact factor: 3.850

6.  Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study.

Authors:  Alison C Johnson; Margarida Matias; Helen Boyle; Bernard Escudier; Alicia Molinier; Brigitte Laguerre; Carole Helissey; Pierre-Emmanuel Brachet; Audrey Emmanuelle Dugué; Loic Mourey; Elodie Coquan; Florence Joly
Journal:  BMC Cancer       Date:  2017-05-22       Impact factor: 4.430
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.